"Our goal is to find novel genes that modify human heart failure by letting the mouse point us in the right direction," said Duke cardiologist Howard Rockman, M.D., noting that 99 percent of mouse genes are shared by humans. "Such genes would provide us the means to identify those heart failure patients having subtle genetic differences that make them more susceptible to poor outcomes."
That information would allow physicians to identify those patients in need of the most aggressive therapies and provide new targets for drug development, Rockman said. He and geneticist Douglas Marchuk, Ph.D., also of Duke, reported their findings in the Dec. 1, 2003, issue of Human Molecular Genetics. The work was supported by the National Institutes of Health, the French Federation of Cardiology and the Burroughs Wellcome Fund.
Heart failure -- a condition characterized by the inability of the heart muscles to pump enough blood to the body's tissues -- affects nearly 5 million patients in the U.S. and is a growing public health concern, Rockman said. Despite the development of novel treatments, the one-year mortality rate for patients with heart failure is as high as 42 percent.
Yet heart failure patients exhibit significant variability in quality of life and survival with the condition, he said. "Following a heart attack, some patients are able to return to their normal lifestyle, while others are horribly debilitated," said Rockman.
In their study, the researchers set out to uncover chromosomal regions containing heart failure modifier genes responsible for some of that dif
Contact: Kendall Morgan
Duke University Medical Center